Jazz Pharmaceuticals plc — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Jazz Pharmaceuticals amended its Non-Employee Director Compensation Policy effective 23 April 2026. The policy sets base annual cash compensation at $75,000 for non-employee directors, with additional committee role fees ranging from $3,125–$100,000 per year (e.g., Board Chair receives $100,000 additional). Annual equity grants of ~$400,000 in RSUs vest after one year. Aggregate annual compensation capped at $750,000 per director ($1.35M for newly appointed directors). No specific changes from prior version disclosed in this document.
Why this rating
Routine governance disclosure; director compensation is standard annual housekeeping. Policy amounts immaterial relative to $6.3B market cap; no operational or financial impact.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.